nach oben

Erschienen in:

01.10.2015 | Research Article

Association of SIRT1 and tumor suppressor gene TAp63 expression in head and neck squamous cell carcinoma

verfasst von: Keiji Kikuchi, Akira Noguchi, Rika Kasajima, Yohei Miyagi, Daisuke Hoshino, Naohiko Koshikawa, Akira Kubota, Tomoyuki Yokose, Yasuo Takano

Erschienen in: Tumor Biology | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Expression of the protein deacetylase SIRT1 is associated with either poor or favorable prognosis in cancer patients, depending on the cancer type. In head and neck squamous cell carcinoma (HNSCC), SIRT1 expression is associated with favorable prognosis. However, the molecular mechanism underlying the tumor-suppressive function of SIRT1 in HNSCC is unknown. SIRT1 promotes differentiation in epithelial cells; therefore, we investigated whether SIRT1 promotes differentiation in HNSCC cells by studying the correlations between the expression of SIRT1 and several genes implicated in stemness or differentiation in HNSCC-derived cell lines. Our results suggest that SIRT1 does not contribute to differentiation in HNSCC cells. RNA interference-mediated reduction of SIRT1 revealed that SIRT1 supports the expression of TAp63, which has been implicated in tumor suppression, in addition to epithelial differentiation. A positive correlation was observed between SIRT1 and TAp63 expression in HNSCC tissues, as determined by quantitative reverse transcription-polymerase chain reaction analysis of RNA extracted from formalin-fixed paraffin-embedded biopsy samples. Together, these results suggest that although SIRT1 does not regulate differentiation of HNSCC cells, it functions as a tumor suppressor in HNSCC by supporting the transcription of tumor-suppressive TAp63. This finding supports the notion that SIRT1-activating drugs could be useful for the treatment of HNSCC.

Nur mit Berechtigung zugänglich

Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004;73:417–35. doi:10.1146/annurev.biochem.73.011303.073651.CrossRefPubMed

Zhang T, Kraus WL. SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions. Biochim Biophys Acta. 2010;1804(8):1666–75. doi:10.1016/j.bbapap.2009.10.022.CrossRefPubMed

Yuan H, Su L, Chen WY. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther. 2013;6:1399–416. doi:10.2147/OTT.S37750.PubMedPubMedCentral

Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol. 2010;5:253–95. doi:10.1146/annurev.pathol.4.110807.092250.CrossRefPubMedPubMedCentral

Sebastian C, Satterstrom FK, Haigis MC, Mostoslavsky R. From sirtuin biology to human diseases: an update. J Biol Chem. 2012;287(51):42444–52. doi:10.1074/jbc.R112.402768.CrossRefPubMedPubMedCentral

Herranz D, Serrano M. SIRT1: recent lessons from mouse models. Nat Rev Cancer. 2010;10(12):819–23. doi:10.1038/nrc2962.CrossRefPubMedPubMedCentral

Villalba JM, Alcain FJ. Sirtuin activators and inhibitors. Biofactors. 2012;38(5):349–59. doi:10.1002/biof.1032.CrossRefPubMedPubMedCentral

Roth M, Chen WY. Sorting out functions of sirtuins in cancer. Oncogene. 2014;33(13):1609–20. doi:10.1038/onc.2013.120.CrossRefPubMed

Noguchi A, Li X, Kubota A, Kikuchi K, Kameda Y, Zheng H, et al. SIRT1 expression is associated with good prognosis for head and neck squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(3):385–92. doi:10.1016/j.oooo.2012.12.013.CrossRefPubMed

10.

Lai CC, Lin PM, Lin SF, Hsu CH, Lin HC, Hu ML, et al. Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumour Biol. 2013;34(3):1847–54. doi:10.1007/s13277-013-0726-y.CrossRefPubMed

11.

Chen IC, Chiang WF, Huang HH, Chen PF, Shen YY, Chiang HC. Role of SIRT1 in regulation of epithelial-to-mesenchymal transition in oral squamous cell carcinoma metastasis. Mol Cancer. 2014;13:254. doi:10.1186/1476-4598-13-254.CrossRefPubMedPubMedCentral

12.

Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, et al. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology. 2009;41(4):366–71. doi:10.1080/00313020902884451.CrossRefPubMed

13.

Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res. 2009;15:4453–9. doi:10.1158/1078-0432.CCR-08-3329.CrossRefPubMed

14.

Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol. 2011;42:204–13. doi:10.1016/j.humpath.2010.05.023.CrossRefPubMed

15.

Chen HC, Jeng YM, Yuan RH, Hsu HC, Chen YL. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol. 2012;19(6):2011–9. doi:10.1245/s10434-011-2159-4.CrossRefPubMed

16.

Noguchi A, Kikuchi K, Zheng H, Takahashi H, Miyagi Y, Aoki I, et al. SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer. Cancer Med. 2014;3(6):1553–61. doi:10.1002/cam4.310.CrossRefPubMedPubMedCentral

17.

Nosho K, Shima K, Irahara N, Kure S, Firestein R, Baba Y, et al. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol. 2009;22:922–32. doi:10.1038/modpathol.2009.49.CrossRefPubMedPubMedCentral

18.

Jang SH, Min KW, Paik SS, Jang KS. Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma. J Clin Pathol. 2012;65(8):735–9. doi:10.1136/jclinpath-2012-200685.CrossRefPubMed

19.

Kikuchi K, Noguchi A, Takahashi H, Zheng H, Kameda Y, Sekiguchi H, et al. High SIRT1 expression and low DBC1 expression are associated with poor prognosis in colorectal cancer. J Cancer Therapeut Res. 2013;2:1–8. doi:10.7243/2050-120X-2-1.CrossRef

20.

Jung W, Hong KD, Jung WY, Lee E, Shin BK, Kim HK, et al. SIRT1 expression is associated with good prognosis in colorectal cancer. Korean J Pathol. 2013;47(4):332–9. doi:10.4132/KoreanJPathol.2013.47.4.332.CrossRefPubMedPubMedCentral

21.

Lv L, Shen Z, Zhang J, Zhang H, Dong J, Yan Y, et al. Clinicopathological significance of SIRT1 expression in colorectal adenocarcinoma. Med Oncol. 2014;31(6):965. doi:10.1007/s12032-014-0965-9.CrossRefPubMed

22.

Milner J. Cellular regulation of SIRT1. Curr Pharmaceut Des. 2009;15:39–44. doi:10.2174/138161209787185841.CrossRef

23.

Deng C. SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci. 2009;5:147–52. doi:10.7150/ijbs.5.147.CrossRefPubMedPubMedCentral

24.

Bosch-Presegué L, Vaquero A. The dual role of sirtuins in cancer. Genes Cancer. 2011;2:648–62. doi:10.1177/1947601911417862.CrossRefPubMedPubMedCentral

25.

Blander G, Bhimavarapu A, Mammone T, Maes D, Elliston K, Reich C, et al. SIRT1 promotes differentiation of normal human keratinocytes. J Invest Dermatol. 2009;129(1):41–9. doi:10.1038/jid.2008.179.CrossRefPubMed

26.

Yuan J, Minter-Dykhouse K, Lou Z. A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol. 2009;185(2):203–11. doi:10.1083/jcb.200809167.CrossRefPubMedPubMedCentral

27.

Mao B, Zhao G, Lv X, Chen HZ, Xue Z, Yang B, et al. Sirt1 deacetylates c-Myc and promotes c-Myc/Max association. Int J Biochem Cell Biol. 2011;43(11):1573–81. doi:10.1016/j.biocel.2011.07.006.CrossRefPubMed

28.

Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Luscher B, et al. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A. 2012;109(4):E187–196. doi:10.1073/pnas.1105304109.CrossRefPubMed

29.

Watt FM, Frye M, Benitah SA. MYC in mammalian epidermis: how can an oncogene stimulate differentiation? Nat Rev Cancer. 2008;8(3):234–42. doi:10.1038/nrc2328.CrossRefPubMedPubMedCentral

30.

Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell. 2010;143(2):313–24. doi:10.1016/j.cell.2010.09.010.CrossRefPubMedPubMedCentral

31.

Evers DL, He J, Kim YH, Mason JT, O’Leary TJ. Paraffin embedding contributes to RNA aggregation, reduced RNA yield, and low RNA quality. J Mol Diagn. 2011;13(6):687–94. doi:10.1016/j.jmoldx.2011.06.007.CrossRefPubMedPubMedCentral

32.

Candi E, Dinsdale D, Rufini A, Salomoni P, Knight RA, Mueller M, et al. TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle. 2007;6(3):274–85. doi:10.4161/cc.6.3.3797.CrossRefPubMed

33.

Mulder KW, Wang X, Escriu C, Ito Y, Schwarz RF, Gillis J, et al. Diverse epigenetic strategies interact to control epidermal differentiation. Nat Cell Biol. 2012;14(7):753–63. doi:10.1038/ncb2520.CrossRefPubMed

34.

Tan DW, Jensen KB, Trotter MW, Connelly JT, Broad S, Watt FM. Single-cell gene expression profiling reveals functional heterogeneity of undifferentiated human epidermal cells. Development. 2013;140(7):1433–44. doi:10.1242/dev.087551.CrossRefPubMedPubMedCentral

35.

Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B. Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun. 2009;383(2):157–62. doi:10.1016/j.bbrc.2009.02.156.CrossRefPubMed

36.

Lim YC, Oh SY, Cha YY, Kim SH, Jin X, Kim H. Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas. Oral Oncol. 2011;47(2):83–91. doi:10.1016/j.oraloncology.2010.11.011.CrossRefPubMed

37.

Chiou S, Yu C, Huang C, Lin S, Liu S, Tsai T, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res. 2013;14:4085–95. doi.CrossRef

38.

Dallaglio K, Petrachi T, Marconi A, Truzzi F, Lotti R, Saltari A, et al. Isolation and characterization of squamous cell carcinoma-derived stem-like cells: role in tumor formation. Int J Mol Sci. 2013;14(10):19540–55. doi:10.3390/ijms141019540.CrossRefPubMedPubMedCentral

39.

Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ. 2011;18(9):1487–99. doi:10.1038/cdd.2011.81.CrossRefPubMedPubMedCentral

40.

Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, et al. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res. 2013;73(6):1855–66. doi:10.1158/0008-5472.CAN-12-3609-T.CrossRefPubMed

41.

Kikuchi K, Tsutsumi K, Ohta Y, Yasumoto S. Time correlation of commitment to calcium-induced apoptosis and terminal differentiation in human ectocervical keratinocytes in suspension cultures. Cell Growth Differ. 1997;8(5):571–9.PubMed

42.

Matsubara R, Kawano S, Kiyosue T, Goto Y, Hirano M, Jinno T, et al. Increased DeltaNp63 expression is predictive of malignant transformation in oral epithelial dysplasia and poor prognosis in oral squamous cell carcinoma. Int J Oncol. 2011;39(6):1391–9. doi:10.3892/ijo.2011.1151.PubMed

43.

Yang X, Lu H, Yan B, Romano RA, Bian Y, Friedman J, et al. DeltaNp63 versatilely regulates a Broad NF-kappaB gene program and promotes squamous epithelial proliferation, migration, and inflammation. Cancer Res. 2011;71(10):3688–700. doi:10.1158/0008-5472.CAN-10-3445.CrossRefPubMedPubMedCentral

44.

Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A, et al. DeltaNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat Cell Biol. 2014;16(10):1004–15. doi:10.1038/ncb3040.CrossRefPubMedPubMedCentral

45.

Sommer M, Poliak N, Upadhyay S, Ratovitski E, Nelkin BD, Donehower LA, et al. DeltaNp63alpha overexpression induces downregulation of Sirt1 and an accelerated aging phenotype in the mouse. Cell Cycle. 2006;5(17):2005–11. doi.CrossRefPubMed

46.

Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, Lowe SW, et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol. 2009;11(12):1451–7. doi:10.1038/ncb1988.CrossRefPubMedPubMedCentral

47.

Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature. 2010;467(7318):986–90. doi:10.1038/nature09459.CrossRefPubMedPubMedCentral

48.

Mattiske S, Ho K, Noll JE, Neilsen PM, Callen DF, Suetani RJ. TAp63 regulates oncogenic miR-155 to mediate migration and tumour growth. Oncotarget. 2013;4(11):1894–903. doi.CrossRefPubMedPubMedCentral

49.

Tan EH, Morton JP, Timpson P, Tucci P, Melino G, Flores ER, et al. Functions of TAp63 and p53 in restraining the development of metastatic cancer. Oncogene. 2014;33(25):3325–33. doi:10.1038/onc.2013.287.CrossRefPubMed

50.

Su X, Gi YJ, Chakravarti D, Chan IL, Zhang A, Xia X, et al. TAp63 is a master transcriptional regulator of lipid and glucose metabolism. Cell Metab. 2012;16(4):511–25. doi:10.1016/j.cmet.2012.09.006.CrossRefPubMedPubMedCentral

Titel: Association of SIRT1 and tumor suppressor gene TAp63 expression in head and neck squamous cell carcinoma
verfasst von: Keiji Kikuchi
Akira Noguchi
Rika Kasajima
Yohei Miyagi
Daisuke Hoshino
Naohiko Koshikawa
Akira Kubota
Tomoyuki Yokose
Yasuo Takano
Publikationsdatum: 01.10.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 10/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3515-y

Neu im Fachgebiet Onkologie

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Association of SIRT1 and tumor suppressor gene TAp63 expression in head and neck squamous cell carcinoma

Abstract

Neu im Fachgebiet Onkologie

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Update Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2015

Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis

High peritumoral Bmi-1 expression is an independent prognosticator of poor prognosis in renal cell carcinoma

CMTM3 inhibits cell growth and migration and predicts favorable survival in oral squamous cell carcinoma

Usefulness of the neutrophil-to-lymphocyte ratio in predicting lymph node metastasis in patients with non-small cell lung cancer

Metformin use improves the survival of diabetic combined small-cell lung cancer patients

A combinatory use of adenoviruses expressing melanoma differentiation-associated gene-7 and replication-competent adenoviruses produces synergistic effects on pancreatic carcinoma cells

Neu im Fachgebiet Onkologie

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Update Onkologie